Submit an Article
Online ISSN: 1945-4589
Impact Journals, LLC. is the publisher of Aging: www.impactjournals.com.
Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.
Impact Journals is a member of the Society for Scholarly Publishing.
Learn about our FREE Post-Publication Promotion Services
Research Paper Volume 16, Issue 1 pp 322—347

Clinical significance and immune characteristics analysis of miR-221-3p and its key target genes related to epithelial-mesenchymal transition in breast cancer

Yutong Fang1,2, *, , Qunchen Zhang3, *, , Zexiao Chen1,2, , Cuiping Guo1,2, , Jundong Wu1,2, ,

  • 1 The Breast Center, Cancer Hospital of Shantou University Medical College, Shantou 515041, Guangdong, China
  • 2 Department of Central Laboratory, Cancer Hospital of Shantou University Medical College, Shantou 515041, Guangdong, China
  • 3 Department of Breast, Jiangmen Central Hospital, Jiangmen 529000, Guangdong, China
* Equal contribution

Received: July 20, 2023       Accepted: November 20, 2023       Published: January 6, 2024      

https://doi.org/10.18632/aging.205370
How to Cite

Copyright: © 2024 Fang et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Background: MicroRNA-221-3p (miR-221-3p) facilitates the advancement of breast cancer (BC) through the induction of epithelial-mesenchymal transition (EMT). Our research aimed to utilize bioinformatics to discover possible EMT-related target genes (ETGs) of miR-221-3p and examine their roles in breast cancer.

Methods: We employed bioinformatics techniques to identify ten key ETGs of miR-221-3p. Subsequently, we conducted an extensive analysis of both miR-221-3p and the ten ETGs, including clinical significance and immune characteristics.

Results: The expression of miR-221-3p was notably higher in Basal-like BC compared to other subtypes and adjacent normal tissue. Our pathway analysis suggested that miR-221-3p might regulate EMT through the MAPK signaling pathway by targeting its ETGs. Among the ETGs, seven core genes (EGFR, IGF1, KDR, FGF2, KIT, FGFR1, and FGF1) exhibited downregulation in BC. Conversely, ERBB2, SDC1, and MMP14 showed upregulation in BC and displayed potential diagnostic value. The analysis of prognostication indicated that increased levels of SDC1 and MMP14 were correlated with an unfavorable prognosis, whereas elevated expression of KIT was associated with a more favorable prognosis. The infiltration of various immune cells and the expression of immune checkpoint genes (ICGs) exhibited positive correlations with most ETGs and miR-221-3p. SDC1 exhibited a greater tumor mutational burden (TMB) score, while ERBB2, KDR, FGF2, KIT, FGFR1, and FGF1 showed lower TMB scores. Furthermore, decreased ERBB2 and KDR expression levels were correlated with elevated microsatellite instability (MSI) scores. Elevated expression of ETGs was linked to decreased mRNA stemness indices (mRNAsi), whereas miR-221-3p displayed the opposite pattern. Most ETGs and miR-221-3p expression exhibited a negative correlation with IC50 values for drugs. Among the ETGs, amplification was the most significant genetic alteration, except for IGF1.

Conclusion: In conclusion, miR-221-3p acts as a unique indicator for Basal-like BC. The examination revealed ten essential ETGs of miR-221-3p, some of which show potential as diagnostic and prognostic markers. The in-depth examination of these ten ETGs and miR-221-3p indicates their participation in the development of BC, emphasizing their promise as innovative targets for therapy in BC patients.

Introduction

Breast cancer (BC) presents a major challenge for women worldwide due to its high incidence rate, with over two million new cases diagnosed annually [1]. A Comprehensive therapeutic strategy is currently used in the treatment of BC patients [2]. Patients with localized BC have a survival rate of over 90% within five years, whereas those with metastatic cancer experience a rate below 30% [3]. Metastasis is the primary reason for more than 90% of cancer-related fatalities in BC [4]. Tumor metastasis is closely linked to the crucial process of epithelial-mesenchymal transition (EMT), where epithelial cells undergo a change into highly mobile mesenchymal cells that possess increased migratory and invasive abilities [5]. The process of epithelial-mesenchymal transition (EMT) has been linked to multiple biological aspects of breast cancer (BC), such as the development of stem cell-like traits [6]. Besides, the process of EMT has been recognized as a crucial element in the immunosuppression within the microenvironment of the tumor, facilitating cancer progression and contributing to drug resistance [7]. Furthermore, substantial evidence suggests that EMT-related genes are linked to therapeutic resistance. Hence, it is crucial to evaluate the influence of gene expression related to EMT in order to develop accurate and individualized therapeutic approaches for BC patients [8].

MicroRNAs (miRNAs) are small RNA molecules that are not involved in coding and have a significant function in regulating gene expression after transcription. Which involved the development and advancement of different human illnesses, such as cancers [9, 10]. Several studies have revealed that miRNAs can trigger the EMT process to promote tumor invasion and metastasis in various malignancies [11]. Furthermore, specific miRNAs related to EMT have been discovered to be linked to the characteristics of cancer stem cells and resistance to drugs [12].

MiRNA-221-3p belongs to the miRNA family that is encoded on the X chromosome in humans. The regulation of its target genes is essential in the growth of different cancerous tumors, as it can either inhibit or facilitate tumorigenesis. [13]. Previous research has provided evidence that miR-221-3p exerts regulatory control over the expression of its target genes, thereby regulating the process of EMT in BC [14, 15]. Considering that miRNAs can regulate multiple targets simultaneously [16], further exploration of the underlying molecular mechanisms through which miR-221-3p regulates the EMT process in BC is warranted.

Considering the information mentioned, our research aimed to discover further possible target genes linked to EMT that are regulated by miR-221-3p. Moreover, our aim was to investigate their clinical importance, their correlation with immune cells that infiltrate tumors, and their influence on drug responsiveness through the utilization of bioinformatics tools. The discovery of these results has the capacity to reveal new targets for therapy in individuals with BC.

Materials and Methods

MiR-221-3p differential expression analysis

Clinical information for BC patients was obtained along with the miR-221-3p expression data from the Cancer Genome Atlas (TCGA) website, which included 1103 BC tissue and 104 normal samples. The expression data of miR-221-3p was displayed in log2(RPM+1) format. Furthermore, we verified the distinct expression of miR-221-3p by utilizing the GSE45666 dataset obtained from the Gene Expression Omnibus (GEO) database and various cell lines. Receiver Operating Characteristic (ROC) curve analysis was performed to assess the discriminatory power of miR-221-3p in distinguishing BC subtypes.

EMT-related target genes (ETGs) identification and enrichment analysis

In order to discover possible target genes of miR-221-3p (Supplementary Table 1), we utilized version 3.0 of miRWalk, a website that integrates prediction results from multiple databases for comprehensive target gene analysis [17]. From the dbEMT 2.0 database [18], a collection of 1184 genes associated with EMT (Supplementary Table 2) was acquired [18]. Furthermore, the R software package limma was used to identify the differentially expressed genes (DEGs) (Supplementary Table 3) using data from TCGA. The criteria of |logFC| > 1 and FDR < 0.05 were applied as thresholds. Subsequently, we pinpointed the common genes shared among the possible target genes of miR-221-3p, the DEGs, and the EMT-related genes, thereby designating them as the possible ETGs of miR-221-3p. For a deeper investigation into the pathways associated with BC progression and the biological roles of the potential ETGs of miR-221-3p, we conducted Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) functional enrichment analyses, which were executed with the R clusterProfiler package. To improve the accuracy of the research, we created a network of protein-protein interactions (PPI) for the ETGs by utilizing the STRING database [19]. The visualization of the network was done using Cytoscape version 3.8.2. For further investigation, the top ten core genes were selected as the ETGs of miR-221-3p using the cytoHubba tool.

Correlation analysis

The RNA-sequencing data for ten ETGs were obtained from the TCGA website. Subsequently, the data were transformed into transcripts per million (TPM) format, represented as log2(TPM+1). Then we analyzed the relation between miR-221-3p and its ETGs, as well as the pairwise relation among the ETGs.

ETGs differential expression analysis

Using data obtained from TCGA, we analyzed the differential expression of ten ETGs between the normal and BC groups. The validation of this analysis was later confirmed by the GSE45666 dataset of the GEO database and cell lines. Additionally, we obtained immunohistochemistry (IHC) images of BC tissues and normal tissues of ten ETGs from the Human Protein Atlas (https://www.proteinatlas.org/) website for further analyzing their expression at the protein level.

Quantitative real-time PCR (qRT-PCR) analysis

The BC cell lines MCF-7 and MDA-MB-231, as well as the breast epithelial cell line MCF-10A, were procured from Procell (Wuhan, China) and cultured following the manufacturer’s guidelines. Total RNA was extracted from the cells using the RNAsimple total RNA kit (Tiangen, Beijing, China) according to the manufacturer’s instructions. Subsequently, qRT-PCR was performed using the PrimeScript™ RT reagent kit (Takara, Japan) and the SYBR Premix Ex Taq™ II (Takara, Japan) as per the manufacturer’s protocol. GAPDH was chosen as the internal reference gene, and the relative expression levels were calculated using the 2−ΔΔCt method. Specific primers used in this study are shown in Table 1.

Table 1. Sequences of all Primers.

Primers sequence (5′–3′)
GAPDH FGTCAAGGCTGAGAACGGGAA
GAPDH RTGGACTCCACGACGTACTCA
EGFR FTCAGCTAGTTAGGAGCCCATTTTT
EGFR RTGTGACTGAACATAACTGTAGGCT
IGF1 FTCTCTAAATCCCTCTTCTGTTTGCT
IGF1 RGGAGATGTTGAGAGCAATGTCAC
ERBB2 FTCTGCTGGCATCAAGAGGTG
ERBB2 RAGCCATCTGGGAACTCAAGC
KDR FGTTCAGACGGGGTTTCTGGT
KDR RTTGGCCAGGAGACACGTAAC
FGF2 FGTGCTAACCGTTACCTGGCT
FGF2 RTCTGCCCAGGTCCTGTTTTG
KIT FAGGTTGTTGAGGCAACTGCT
KIT RATGGTGCAGGCTCCAAGTAG
FGFR1 FGAGCCTTGTCACCAACCTCT
FGFR1 RAAGCATCTCACCGAAATCCCG
SDC1 FGGAAGGGCCTGTGGGTTTAT
SDC1 RCTGCTCGATGCTCTCTTGGG
FGF1 FCGGCTCAACACCAAATGAGG
FGF1 RTCTGGCCATAGTGAGTCCGA
MMP14 FCCGATGTGGTGTTCCAGACA
MMP14 RTCGTATGTGGCATACTCGCC
MiR-221-3p FGTTCGTGGGAGCTACATTGTCTGC
MiR-221-3p RGTGTCGTGGAGTCGGCAATTC
MiR-221-3p RT PrimerGTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACGAAACCCA

IHC staining and scoring

We used tissue microarrays (F048Br01a, Bioaitech, China) comprising 24 BC tissues of varying stages and grades, along with their corresponding adjacent tumor tissues. IHC staining and scoring were conducted following a previously described protocol [20]. In summary, following the removal of paraffin, rehydration, and microwave antigen retrieval, the slides were left to incubate with antibodies overnight at a temperature of 4 degrees Celsius. Anti-ERBB2 (ab237715, Abcam), anti-SDC1 (ab130405, Abcam), and anti-MMP14 (ab51074, Abcam) were each diluted to concentrations of 1:2000, 1:1000, and 1:800, respectively. Afterward, the slides were subjected to secondary antibodies at ambient temperature for a duration of 30 minutes. Then, they were stained using DAB substrate and subsequently counterstained with hematoxylin.

ETGs clinical significance analysis

The diagnostic value of the upregulated ETGs was evaluated through ROC curve analysis, and the findings were subsequently confirmed using the GSE45666 dataset. To assess the clinical significance of the ETGs, we conducted an analysis of their expression in relation to clinical stages and PAM50 subtypes of BC. Furthermore, to investigate the correlation between the ETGs expression and the prognosis, we stratified the BC patients into two groups according to the median ETGs expression value. Subsequently, the Kaplan-Meier (KM) survival analysis was conducted to analyze the relationship between ETGs expression and patient prognosis, encompassing both overall survival (OS) and the disease-specific survival (DSS).

Immune characteristics analysis

To investigate the correlation between ETG expression and immune cells, we employed the single-sample gene set enrichment analysis method [21] to evaluate the infiltration enrichment of 24 common immune cell types. This enabled us to conduct further correlation analysis between ETGs expression and immune cell infiltration levels. Furthermore, the correlation between eight immune checkpoint genes (ICGs) and ETGs expression was analyzed.

Tumor mutational burden (TMB), microsatellite instability (MSI) and stemness analysis

TMB and MSI scores were derived from prior research [22, 23]. The one-class logistic regression machine-learning algorithm [24] facilitated the computation of the mRNA expression-based stemness index (mRNAsi) score. Analysis of the difference of the TMB, MSI and mRNAsi scores between the high and low expression groups of ten ETGs and miR-221-3p was conducted.

Drug sensitivity analysis

To predict the drug response of individual samples obtained from TCGA, we employed the R pRRophetic package. Afterward, the IC50 values for each sample’s drug sensitivity were estimated using Ridge’s regression, utilizing data acquired from the Genomics of Drug Sensitivity in Cancer database [25]. Additionally, we conducted further analysis on the association between the IC50 values and the expression of the ETGs and miR-221-3p.

Genetic alteration analysis

We utilized the cBioPortal website to analyze genetic alterations in the BC cohort. Moreover, we examined OS and DSS in both the altered and unaltered groups.

Statistical analysis

The unpaired t-test was used to analyze statistical differences between two groups, whereas the Kruskal-Wallis test was employed for comparing multiple groups. Expression level values were presented as means ± standard deviations. Correlation analysis utilized Spearman’s correlation test. Statistical analyses and plotting were made easier with the help of R software (version 4.2.1) and GraphPad Prism (version 8.0). Statistically significant findings were determined in this study for P-values less than 0.05.

Availability of data and materials

The data underlying this study are freely available from TCGA (https://portal.gdc.cancer.gov/), GEO (http://www.ncbi.nlm.nih.gov/geo/), miRWalk 3.0 (http://mirwalk.umm.uni-heidelberg.de/), dbEMT 2.0 (http://dbemt.bioinfo-minzhao.org/index.html), Human Protein Atlas (https://www.proteinatlas.org/) and cBioPortal databases (http://www.cbioportal.org).

Results

The clinical significance and differential expression of miR-221-3p

The differential expression analysis of miR-221-3p revealed that miR-221-3p levels were lower in BC tissues compared to normal tissues (p = 0.001). In Figure 1A, the expression levels in BC tissues and normal tissues were 6.509 ± 1.082 and 6.884 ± 0.557, respectively. The GSE45666 dataset also confirmed the identical outcome (p < 0.05) (Figure 1B). Moreover, miR-221-3p expression was decreased in MCF-7 and notably increased in MDA-MB-231 (Figure 1C). Furthermore, as shown in Figure 1D, the higher expression of miR-221-3p was linked to the negative status of estrogen receptor (ER) (p < 0.001) and progesterone receptor (PR) (p < 0.001), as well as human epidermal growth factor receptor 2 (HER2) (p = 0.004). Additionally, miR-221-3p expression was found to be reduced in BC patients with nodal status N1 in comparison to individuals without lymph node metastases (p = 0.044). Significantly, miR-221-3p expression in the Basal-like subtype was 7.379 ± 1.081, markedly higher than that in Luminal A (6.303 ± 0.975, p < 0.001), Luminal B (6.214 ± 1.013, p < 0.001), and HER2-enriched subtypes (6.380 ± 0.845, p < 0.001). Due to the high expression in Basal-like BC, we further prove miR-221-3p is a special biomarker of which to discriminate from other subtypes. Using a cut-off value of 7.037, the ROC curve analysis yielded an area under the curve (AUC) of 0.791, with a specificity of 63.9% and sensitivity of 84.0% (Figure 1E).

MiR-221-3p differential expression in BC and normal adjacent tissues based on TCGA database (A) and validated by the GSE45666 dataset (B) and cell lines (C). The clinical significance of miR-221-3p expression (D). ROC curve shows the discriminative power of miR-221-3p between the Basal-like subtype and others (E). In the present study, NS indicates no statistical difference, *P **P ***P ****P

Figure 1. MiR-221-3p differential expression in BC and normal adjacent tissues based on TCGA database (A) and validated by the GSE45666 dataset (B) and cell lines (C). The clinical significance of miR-221-3p expression (D). ROC curve shows the discriminative power of miR-221-3p between the Basal-like subtype and others (E). In the present study, NS indicates no statistical difference, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.

ETGs identification and enrichment analysis

As shown in the Venn diagram (Figure 2A), 35 genes were selected as possible ETGs of miR-221-3p. The subsequent GO analysis of these 35 genes revealed that they may play a role in regulating biological processes related to epithelial cell proliferation and transmembrane receptor protein tyrosine kinase activity. Furthermore, the KEGG pathway analysis suggested that these ETGs might play a role in controlling the EMT process via the MAPK signaling pathway and could potentially be linked to the resistance of EGFR tyrosine kinase inhibitors in the BC treatment (Figure 2B; Supplementary Table 4). Figure 2C shows the construction of a PPI network of 35 ETGs, including 26 nodes and 78 edges. In order to enhance the precision of predictions, we have identified the top ten core genes from the PPI network for further investigation. These core genes included EGFR, IGF1, ERBB2, KDR, FGF2, KIT, FGFR1, SDC1, FGF1, and MMP14 (Figure 2D).

The Venn diagram shows DEGs, EMT-related genes, and possible targets of miR-222-3p (A). GO and KEGG pathway enrichment analysis of 35 ETGs (B). The PPI network of 35 ETGs (C). 10 top core genes of the PPI network were identified as the ETGs of miR-221-3p for further research (D).

Figure 2. The Venn diagram shows DEGs, EMT-related genes, and possible targets of miR-222-3p (A). GO and KEGG pathway enrichment analysis of 35 ETGs (B). The PPI network of 35 ETGs (C). 10 top core genes of the PPI network were identified as the ETGs of miR-221-3p for further research (D).

Correlation analysis

Correlation analysis revealed that seven out of the ten ETGs exhibited a significant correlation with miR-221-3p expression. The results depicted in Figure 3A indicate that the levels of EGFR (r = 0.227, p < 0.001), FGF2 (r = 0.132, p < 0.001), KIT (r = 0.114, p < 0.001), SDC1 (r = 0.061, p = 0.045), and MMP14 (r = 0.087, p = 0.004) exhibited a positive correlation with miR-221-3p expression. In contrast, miR-221-3p expression showed a negative correlation with ERBB2 (r = −0.318, p < 0.001) and KDR (r = −0.121, p < 0.001). Moreover, the ETGs were evaluated for pairwise correlation, and the majority of them exhibited positive correlation with one another (Figure 3B). Additionally, it was observed that there were negative correlations between EGFR and ERBB2 (r = −0.142, p < 0.001), FGF2 and ERBB2 (r = −0.088, p = 0.003), and FGF2 and SDC1 (r = −0.108, p < 0.001).

The correlation between miR-221-3p and its ETGs expression (A). The pairwise correlation among the ETGs expression (B).

Figure 3. The correlation between miR-221-3p and its ETGs expression (A). The pairwise correlation among the ETGs expression (B).

ETGs differential expression analysis

The result of the differential expression indicated that seven out of ten ETGs had reduced expression levels in the tumor group compared to the normal group (Figure 4A). These ETGs were EGFR, IGF1, KDR, FGF2, KIT, FGFR1 and FGF1. In contrast, ERBB2, SDC1, and MMP14 exhibited elevated expression levels in the tumor group (All p < 0.05). Furthermore, the GSE109169 dataset was utilized to validate the differential expression of the ETGs, as depicted in Figure 4B. In addition, the analysis of ETGs in cell lines validated the same outcomes (Figure 4C). Figure 5 displays the immunohistochemistry images acquired from the HPA database (https://www.proteinatlas.org/) (Supplementary Table 5) for the analysis of ETGs protein expression. The majority of ETGs showed consistent protein expression with the previous analyses in tissue samples. However, the protein expression of IGF1, KDR and FGF2 were not detected in both BC tissue and normal tissue. Moreover, IHC staining was conducted to confirm the protein expression of three ETGs that were upregulated. We utilized tissue microarrays containing 24 instances of BC tissues and their corresponding neighboring tumor tissues. According to the findings, in 14 out of 24 cases (58.3%) ERBB2 expression was upregulated in BC tissues compared to the corresponding paracancerous tissues, while SDC1 expression was upregulated in 18 out of 24 cases (75.0%). Additionally, 17 out of 24 cases (70.8%) exhibited increased expression. Supplementary Figure 1 contains representative IHC images.

Differential expression of 10 ETGs in BC and normal adjacent tissues based on TCGA database (A) and validated by the GSE109169 dataset obtained from the GEO database (B) and cell lines (C).

Figure 4. Differential expression of 10 ETGs in BC and normal adjacent tissues based on TCGA database (A) and validated by the GSE109169 dataset obtained from the GEO database (B) and cell lines (C).

Protein expression of 10 ETGs.

Figure 5. Protein expression of 10 ETGs.

The diagnostic significance of the upregulated ETGs

Furthermore, we evaluated the possible diagnostic significance of the upregulated ETGs. The ROC curves for ERBB2, MMP14, and SDC1 are illustrated in Figure 6A. When the threshold value was set at 7.007, the AUC for ERBB2’s ROC curve was 0.702, with a sensitivity of 87.6% and a specificity of 45.6%. When the threshold was set at 7.728, the AUC for MMP14’s ROC curve was 0.794, demonstrating a sensitivity of 92.0% and a specificity of 66.1%. Significantly, SDC1 exhibited the greatest AUC of 0.847 among the ETGs that were upregulated, demonstrating a sensitivity of 85.0% and a specificity of 71.8% when the threshold was established at 7.538. Figure 6B demonstrates the validation of the diagnostic values of the upregulated ETGs using the GSE45666 dataset.

ROC curves show the diagnostic values of 3 upregulated ETGs (A) and are validated by the GSE109169 dataset (B).

Figure 6. ROC curves show the diagnostic values of 3 upregulated ETGs (A) and are validated by the GSE109169 dataset (B).

ETGs clinical significance analysis

Our study examined the association between ETGs expression and both clinical stages and PAM50 subtypes of BC. As depicted in Figure 7A, in terms of clinical stages, the majority of ETGs exhibited no notable variations in expression across different stages. Nevertheless, the examination in Figure 7B exposed connections between ETGs manifestation and PAM50 subtypes. In particular, the Basal-like subtype exhibited a tendency towards increased expression of EGFR and KIT in comparison to the other subtypes. Conversely, the Basal-like BC exhibited decreased expression of KDR. Luminal A subtype showed increased expression of IGF1 and FGF1. Furthermore, the levels of ERBB2 and SDC1 were elevated in the HER2-enriched BC. In the Luminal subtypes, FGFR1 showed increased expression, while FGF2 showed elevated expression in both Luminal A and Basal-like BC compared to the remaining subtypes.

The association between 10 ETGs expression and pathologic stage (A) and PAM50 subtype (B).

Figure 7. The association between 10 ETGs expression and pathologic stage (A) and PAM50 subtype (B).

Evaluation of the ETGs prognosis

KM survival curves were generated to analyze the prognosis and the results are presented in Figure 8. It was observed that BC patients who had elevated levels of SDC1 expression experienced poorer DSS (HR = 2.21, p = 0.001) and OS (HR = 1.60, p = 0.004). Notably, a decrease in KIT expression was linked to a poorer DSS outcome (HR = 0.62, p = 0.028), although there was no significant statistical variation in OS. Moreover, increased MMP14 expression was associated with poorer DSS outcomes (HR = 1.57, p = 0.040), while no significant correlation was observed with OS.

KM survival curves analysis of 10 ETGs.

Figure 8. KM survival curves analysis of 10 ETGs.

Immune infiltration analysis

The results of the immune infiltration analysis are depicted in Figure 9A. We observed that several ETGs, particularly EGFR, IGF1, KDR, FGF2, and KIT, exhibited significant positive correlations with various immune cell infiltrations. Among them, IGF1 showed the strongest positive correlation with CD8+ T cells (r = 0.444), cytotoxic cells (r = 0.366), dendritic cells (DCs) (r = 0.408), eosinophils (r = 0.491), immature DCs (iDCs) (r = 0.571), mast cells (r = 0.464), natural killer (NK) cells (r = 0.486), plasmacytoid DCs (pDCs) (r = 0.425), T cells (r = 0.414), T effector memory (Tem) cells (r = 0.39), and T follicular helper (TFH) cells (r = 0.337) (all p < 0.001). On the other hand, a negative correlation between ETG expression and immune infiltration was mainly observed in ERBB2, which exhibited the strongest negative correlation with activated DCs (aDCs) (r = −0.226), B cells (r = −0.140), cytotoxic cells (r = −0.179), DCs (r = −0.129), macrophages (r = −0.174), NK CD56- cells (r = −0.166), T cells (r = −0.150), type 1 Th (Th1) cells (r = −0.243), and regulatory T (Treg) cells (r = −0.180) (all p < 0.001), as well as gamma delta T (Tgd) cells (r = −0.079, p = 0.008). Moreover, as illustrated in Figure 9B, the miR-221-3p expression exhibited noteworthy positive associations with the majority of immune cell categories, notably Th1 lymphocytes (r = 0.413, p < 0.001), aDCs (r = 0.386, p < 0.001), and macrophages (r = 0.382, p < 0.001). In contrast, the expression of miR-221-3p showed a notable inverse association with eosinophils (r = −0.174, p < 0.001) and mast cells (r = −0.100, p = 0.001).

Comparison of infiltration levels in 24 common immune cells between low and high expression groups of 10 ETGs (A) and miR-221-3p (B).

Figure 9. Comparison of infiltration levels in 24 common immune cells between low and high expression groups of 10 ETGs (A) and miR-221-3p (B).

Correlation with the ICGs expression

The findings from Figure 10A indicated that most ETGs controlled by miR-221-3p displayed a positive association with ICGs expression. However, the inverse relationship primarily existed between ERBB2 and ICGs, especially LAG3 (r = −0.229), PDCD1LG2 (r = −0.159), TIGIT (r = −0.155), and PDCD1 (r = −0.109) (all p < 0.001). In addition, as depicted in Figure 10B, miR-221-3p displayed a notable association with eight ICGs, out of which it solely demonstrated an inverse correlation with SIGLEC15 (r = −0.170, p < 0.001).

Correlation between ICGs and ETGs expression (A), and correlation between ICGs and miR-221-3p expression (B).

Figure 10. Correlation between ICGs and ETGs expression (A), and correlation between ICGs and miR-221-3p expression (B).

TMB and MSI analysis

TMB has become a significant indicator for forecasting the effectiveness of immunotherapy and has been extensively researched in different forms of cancer. Figure 11A demonstrates a positive correlation between higher expression of IGF1 (p < 0.001), ERBB2 (p < 0.001), KDR (p = 0.006), FGF2 (p = 0.002), KIT (p = 0.035), FGFR1 (p < 0.001), and FGF1 (p = 0.005) with lower TMB scores. Furthermore, solely elevated SDC1 expression exhibited a correlation with an increased TMB score (p = 0.014). Additionally, we examined the correlation between MSI scores and the levels of expression of ETGs, as shown in Figure 11B. The findings from our study indicated that higher MSI scores were linked to decreased expression of ERBB2 and KDR (p = 0.036; p = 0.002, respectively). Moreover, individuals exhibiting elevated levels of miR-221-3p expression displayed a tendency towards increased MSI scores (p = 0.038) as depicted in Figure 11C.

The TMB scores (A) and MSI scores (B) between the high and low expression groups of 10 ETGs. The TMB and MSI scores between the high and low expression groups of miR-221-3p (C).

Figure 11. The TMB scores (A) and MSI scores (B) between the high and low expression groups of 10 ETGs. The TMB and MSI scores between the high and low expression groups of miR-221-3p (C).

Stemness analysis

The mRNAsi scores were compared between groups with high expression and low expression. According to Figure 12, there was a significant correlation (p < 0.001 for all) between increased expression of ETGs and decreased mRNAsi scores. Conversely, elevated levels of miR-221-3p showed a tendency towards increased mRNAsi scores (p = 0.049).

The mRNAsi scores between the high and low expression groups of 10 ETGs (A) and miR-221-3p (B).

Figure 12. The mRNAsi scores between the high and low expression groups of 10 ETGs (A) and miR-221-3p (B).

Drug sensitivity analysis

The analysis shown in Figure 13A indicated a majority of ETGs displayed a negative association with the IC50 values. Notably, EGFR exhibited the most robust correlation with IC50 values for doxorubicin (r = −0.297), paclitaxel (r = −0.401), cisplatin (r = −0.560), gemcitabine (r = −0.285), and tamoxifen (r = −0.394) (all p < 0.001). Conversely, positive association predominantly existed between the IC50 values and both ERBB2 and FGFR1. Furthermore, Figure 13B revealed a negative correlation between miR-221-3p expression and seven drug IC50 values (all p < 0.001), except for lapatinib which showed a positive correlation with miR-221-3p expression (r = 0.206, p < 0.001).

The correlation between the IC50 of 8 drugs and ETGs expression (A) and miR-221-3p expression (B).

Figure 13. The correlation between the IC50 of 8 drugs and ETGs expression (A) and miR-221-3p expression (B).

ETGs genetic alteration analysis

The examination of genetic alteration of the ETGs depicted in Figure 14A indicated that amplification was the main type of genetic alteration observed in nine ETGs, except for IGF1, which had a genetic alteration rate of only 0.5%. Among the ten ETGs, ERBB2 had the highest genetic alteration rate, reaching 14%. However, there was no notable disparity in OS and DSS between the ETGs-altered group and the unaltered group (Figure 14B, 14C). Furthermore, the OS of the unaltered group and the main ETGs-altered groups (EGFR, ERBB2, and FGFR1) were also analyzed (Figure 14D). The median OS in months (95% CI) for the unaltered group was 129.70, which was longer than that of the FGFR1-altered group (127.33) but shorter than the EGFR (140.28) and ERBB2-altered group (146.50).

Analysis of genetic alteration of 10 ETGs (A). The KM survival curves show the OS and DSS between the ETGs altered group and the unaltered group (B, C). The KM survival curve shows the OS of the ETGs-unaltered group and the ETGs-altered groups of EGFR, ERBB2 and FGFR1 (D).

Figure 14. Analysis of genetic alteration of 10 ETGs (A). The KM survival curves show the OS and DSS between the ETGs altered group and the unaltered group (B, C). The KM survival curve shows the OS of the ETGs-unaltered group and the ETGs-altered groups of EGFR, ERBB2 and FGFR1 (D).

Discussion

Typically, early-stage BC patients have a positive prognosis and a high chance of being cured. Nevertheless, the poor prognosis of metastatic BC poses a considerable public health obstacle. Over the past few years, there has been an increasing fascination with the phenomenon of EMT as a pivotal process implicated in the spread of tumors [5]. The progression of BC is influenced by the participation of multiple miRNAs in the regulation of EMT. These miRNAs can have tumor-suppressing or tumor-promoting effects and may serve as potential therapeutic targets [11, 26]. It has been demonstrated that miR-221-3p is a regulator of EMT in BC [14, 15, 27]. Using bioinformatic analyses, we identified ten genes associated with EMT that are targeted by miR-221-3p. Additionally, we delved into the potential mechanisms that regulate these genes.

In this study, miR-221-3p expression was observed to be reduced when compared to the adjacent normal tissues. The validation of this finding was additionally confirmed in the MCF-7 cell line through qRT-PCR. However, prior research has consistently indicated elevated levels of miR-221-3p expression in blood and tissue samples from individuals with BC [28, 29]. These discrepancies could be attributed to small sample sizes and regional differences in patient selection, mainly in Asian populations, which may have contributed to inconsistent results. Our research uncovered a noteworthy increase in the expression of miR-221-3p in MDA-MB-231 cells. Furthermore, the analysis of PAM50 subtypes indicated a considerably higher expression in the Basal-like subtype when compared to other subtypes of BC and normal tissues. These findings align with previous studies [14, 15, 30]. The ROC analysis indicated that miR-221-3p could potentially function as a distinctive biomarker for Basal-like BC. Moreover, the miR-221-3p’s clinical significance suggests that its elevated levels were inversely linked to the status of ER, PR, and HER2. Studies have shown that the excessive presence of miR-221-3p hinders the translation of ER. However, ER has the ability to repress the expression of miR-221-3p through the recruitment of nuclear receptor corepressor and thyroid hormone receptor [31]. The specific relationship between miR-221-3p and PR or HER2 remains unclear. Furthermore, our investigation uncovered the correlation between miR-221-3p expression and the infiltration of immune cells, along with ICGs, indicating its potential involvement in the regulation of the immune microenvironment in BC. Moreover, we discovered a direct association between the miR-221-3p expression and mRNAsi scores, suggesting that individuals with elevated levels of miR-221-3p in BC exhibited reduced levels of differentiation and increased cellular stemness.

The pathway enrichment analysis in our research indicated that miR-221-3p has the potential to control the process of EMT through the MAPK signaling pathway. Abnormal activation of the p38 MAPK signaling pathway in BC cells has been demonstrated to promote EMT, one of the three primary components of the MAPK signaling pathway [32]. For our research, we identified ten key target genes related to EMT of miR-221-3p for subsequent analysis.

The epidermal growth factor receptor (EGFR), a transmembrane protein, is essential for controlling cellular processes like growth, development, and viability. MiR-221-3p has been recognized in recent research as a regulator of the EGFR signaling pathway that enhances EMT [33, 34]. Based on the findings of this research, miR-221-3p exhibits a strong association with EGFR, which emerging as the top core ETG, and there is also a positive correlation in their expression levels. The results indicate that the combination of miR-221-3p and EGFR activation may collaborate in enhancing EMT in BC through the establishment of a beneficial cycle. According to reports, EGFR overexpression is found in 15-30% of cases of BC, and overexpression is observed in at least 50% of Basal-like BC [34, 35]. Furthermore, we noticed a substantial increase in the expression of EGFR in Basal-like BC in comparison to other subtypes, suggesting a potential correlation between its overabundance and the invasion of BC. Furthermore, our findings indicate a correlation between the elevated levels of EGFR and the presence of immune cell infiltrates and ICGs. This implies that individuals diagnosed with BC who exhibit high EGFR expression might experience greater advantages from immune checkpoint inhibitor therapy. In recent times, the treatment of Basal-like BC [36] has been effectively demonstrated by the emerging therapy of chimeric antigen receptor T-cell that specifically targets EGFR. EGFR seems to be a promising therapeutic focus for treating Basal-like BC, as indicated by these findings.

Insulin-like growth factor 1 (IGF1) is crucial in the metabolic function of hepatocytes and the overall metabolism of the body [37]. Previous experimental findings demonstrated that IGF1 facilitates the activation of EMT through the MAPK and PI3K/AKT pathways, consequently promoting the metastasis of BC cells [38]. This study revealed that IGF1 exhibited the strongest positive association with the majority of immune cells, including CD8+ T cells, DCs, NK cells, and T cells. This suggests that IGF1 signaling molecules could potentially attract immune cells within the tumor microenvironment. Nevertheless, there is a scarcity of prior research on the impact of IGF1 signaling on immune cells in BC. Consequently, further experiments are necessary to uncover its function to anti-tumor immunity.

Erb-b2 receptor tyrosine kinase 2 (ERBB2), also known as HER2, is a receptor tyrosine kinase belonging to the EGFR family. It is amplified and overexpressed in over 20% of BC cases, leading to an unfavorable prognosis [39]. Multiple pieces of evidence indicate that ERBB2 has the ability to trigger EMT in BC cells by engaging with various pathways associated with stemness, leading to the development of resistance to trastuzumab [40]. Moreover, the excessive expression of ERBB2 in breast epithelial cells has the ability to trigger EMT and enhance oncogenic capacity, which can be suppressed by the concurrent presence of EGFR [41]. In our present investigation, we discovered an inverse association between the expression of ERBB2 and numerous infiltrations of immune cells, indicating that ERBB2 may also play a role in suppressing the immune response in BC. The presence of ERBB2 was also discovered to have a positive correlation with the IC50 values of chemotherapeutic medications, indicating that ERBB2 signaling could potentially be involved in the development of resistance to chemotherapy.

Kinase inserts domain receptor (KDR), also called VEGFR2, is a receptor for vascular endothelial growth factor and plays a crucial role in regulating angiogenesis in BC. Overexpression of KDR is linked to the aggressive advancement of BC [42, 43]. Furthermore, there have been reports indicating a correlation between elevated KDR expression and the heightened expression of proteins associated with EMT in BC. However, the precise mechanism remains unknown [43]. Additionally, there were reports indicating that elevated KDR expression can facilitate the conversion of BC from Basal-like to Luminal phenotype and improve the responsiveness to Tamoxifen therapy, which is linked to a favorable prognosis [44]. In this study, we observed comparable results where the luminal-like subtype exhibited elevated levels of KDR expression compared to the Basal-like subtype. Furthermore, heightened KDR expression was linked to reduced responsiveness to various drugs, including Tamoxifen. The role of KDR in BC remains controversial and deserves further exploration.

As a member of the fibroblast growth factor (FGF) family, FGF2 is a growth factor derived from cancer-associated fibroblasts that stimulate BC cell proliferation and migration [45, 46]. Interestingly, another study found that FGF2 can reverse the TGF-β signaling pathway to suppress the growth and migration of BC cells [47]. Although FGF2 has been identified as an EMT activator in the progression of cancers [48, 49], studies about its EMT-related regulatory mechanisms in BC are limited. Our finding reveals for the first time that FGF2 might recruit immune cells and enhance the drug sensitivity to exert an anti-tumor effect in BC.

The KIT proto-oncogene receptor tyrosine kinase (KIT) gene codes for the cluster of differentiation 117, a receptor tyrosine kinase responsible for controlling cellular growth and viability [50]. The expression and function of KIT in BC have been a topic of considerable controversy. On the one hand, prior research has indicated that the occurrence of KIT expression in patients with Basal-like BC is higher compared to patients with other subtypes, and an elevated KIT expression level is linked to the advancement of tumors [51, 52]. In this research, we discovered a similar result indicating that the level of KIT expression is higher in Basal-like BC compared to other subcategories. Conversely, certain studies have indicated that the absence of KIT is detected while breast cancer is progressing and is associated with the occurrence of malignancy [53, 54]. In line with these results, our study revealed a decrease in KIT expression in BC tissues compared to normal tissues. Additionally, patients with elevated KIT expression had a longer DSS period. Furthermore, it was discovered that increased KIT expression is associated with elevated immune infiltration and expression of ICGs, as well as decreased drug sensitivity and stemness. This suggests that BC patients with higher levels of KIT expression are more likely to respond well to treatment and have a favorable prognosis. The possible reason for the controversial role of KIT in BC could be explained by tissue specificity [53]. KIT might mainly function as a tumor suppressor gene in BC but promote the malignant transformation in the Basal-like subtype, which deserves further in-depth studies.

As a member of the fibroblast growth factor receptor (FGFR) family, FGFR1 shows a high affinity for FGF2 to stimulate the growth and progression of BC cells [45]. FGFR1 was recently demonstrated as an EMT marker and its interaction with β3 integrin is required to the FGF2-facilitate metastatic outgrowth in BC [55]. The co-expression between FGFR1 and FGF2 was also found in this study. Additionally, it was reported that FGFR1 amplification mainly existed in the Luminal subtype and is related to adverse prognosis [56, 57]. We found similar outcomes in this study, the amplification rate of FGFR1 in the TCGA dataset was up to 13%, and the median months overall of the FGFR1 altered BC patients was 127.33, shorter than the unaltered group. Hence, it is imperative to conduct additional research on FGFR1 as a plausible target for therapeutic intervention in BC.

Syndecan-1 (SDC1), a heparan sulfate proteoglycan, is part of the syndecan family and is crucial in the advancement of cancer [58]. In this study, we discovered that the SDC1 demonstrates a greater level of expression in BC, particularly in the HER2-enriched subtype. Additionally, BC patients with elevated SDC1 levels are more likely to experience a negative prognosis. These findings align with previous investigations [59–61]. Furthermore, the AUC value of the diagnostic ROC curve is 0.847, indicating that SDC1 has the potential to be a biomarker for the diagnosis of BC, with a sensitivity of 85.0% and specificity of 71.8%.

FGF1 is part of the FGF family, known for its role in promoting angiogenesis [62]. It was observed that FGF1 expression in mammary epithelial cells can augment EMT induced by TGF-β1 [63], which might be crucial to the occurrence of BC. In line with a prior investigation, our findings indicate that the levels of FGF1 in BC tissues are comparatively reduced compared to those in normal breast tissues, implying that FGF1 primarily functions as a differentiating agent in normal tissues rather than a factor promoting growth. Nevertheless, the involvement of FGF1 expression in BC has been documented in the invasion and spread of BC. Additionally, the antibody scFv1C9, specific to FGF1, has demonstrated its ability to decrease the density of microvessels in BC tissues and hinder the lung metastasis of BC [64–66]. These findings highlight the potential of IGF1 as a target for effective BC treatment.

As a member of the matrix metalloproteinase (MMP) family, MMP14 is overexpressed in BC tissues and participates in the pathogenesis and metastasis of BC [67]. Correlative evidence suggests that high MMP14 expression in cancers is significantly correlated with adverse prognosis [68–70], and it was observed that BC patients with high MMP14 expression have a shorter DSS. It was the first time we found that MMP14 exhibited a high correlation with immune cells, ICGs expression, and drug sensitivity in BC. Additionally, by the ROC analysis, we found that MMP14 might be a diagnostic biomarker for BC. It has been demonstrated that the MMP family is crucial in regulating the EMT process in cancers [71, 72], however, the EMT-associated mechanism of MMP14 involved in BC has not been reported, we supposed that miR-221-3p might upregulate the MMP14 expression in BC to promote EMT, which deserves our further study.

Further validation is necessary for the present study, as it primarily relied on data acquired from the TCGA database. To overcome these limitations, it is recommended to conduct the luciferase reporter assay as an initial measure in order to confirm the correlation between miR-221-3p and its ETGs. Secondly, further research should be conducted on the EMT-regulated mechanisms associated with ETGs. Moreover, it is imperative to explore the potential of employing ETGs as targets for therapy in the upcoming time. The results of this study have implications for future research on the EMT mechanism of BC, potentially offering effective treatment approaches for individuals afflicted by the condition.

Conclusion

To summarize, our research revealed that miR-221-3p is upregulated in Basal-like BC, functioning as a distinctive indicator for differentiating it from other subtypes of BC. Ten core ETGs of miR-221-3p were identified, and SDC1 and MMP14 could potentially function as valuable indicators for the diagnosis of BC and the prediction of unfavorable prognosis. The comprehensive analysis of these ten ETGs indicates their possible involvement in the tumor microenvironment during the development of BC. These findings highlight the promising therapeutic targets for BC patients.

Abbreviations

BC: breast cancer; EMT: epithelial-mesenchymal transition; miRNAs: MicroRNAs; miR-221-3p: microRNA-221-3p; TCGA: The Cancer Genome Atlas; RPM: read per million; GEO: Gene Expression Omnibus; DEGs: differentially expressed genes; ETGs: EMT-related target genes; GO: Gene Ontology; KEGG: Kyoto Encyclopedia of Genes and Genomes; PPI: protein-protein interaction; TPM: Transcripts Per Million; ROC: Receiver Operating Characteristic; qRT-PCR: quantitative real-time PCR; IHC: immunohistochemistry; KM: Kaplan-Meier; OS: overall survival; DSS: disease-specific survival; ICGs: immune checkpoint genes; TMB: tumor mutational burden; MSI: microsatellite instability; mRNAsi: mRNA expression-based stemness index; HER2: human epidermal growth factor receptor 2; ER: estrogen receptor; PR: progesterone receptor; AUC: area under the curve; EGFR: epidermal growth factor receptor; IGF1: insulin-like growth factor 1; ERBB2: Erb-b2 receptor tyrosine kinase 2; KDR: kinase insert domain receptor; FGF: fibroblast growth factor; KIT: KIT proto-oncogene receptor tyrosine kinase; FGFR: fibroblast growth factor receptor; SDC1: syndecan-1; MMP: matrix metalloproteinase.

Author Contributions

Y.T.F organized the article writing and critically modified the manuscript. Y.T.F and Z.X.C performed the IHC experiment. J.D.W modified the manuscript. Q.C.Z drafted the manuscript and were responsible for the acquisition of data and analysis; Z.X.C contributed to the literature search. C.P.G check and correct language expression. All authors read and approved the manuscript and agree to be accountable for all aspects of the research in ensuring that the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Conflicts of Interest

The authors declare no conflicts of interest related to this study.

Ethical Statement

This study does not involve animal or clinical experiments. All data were obtained from public databases, and therefore, it does not require submission for ethical review.

Funding

This work was supported by the Youth Science Foundation of the Cancer Hospital of Shantou University Medical College (Grant No. 2023A002), the Foundation of Basic and Applied Basic Research of Guangdong Province, China (No. 2022A1515220202), and the 2023 Science and Technology Innovation Strategy Project of Guangdong Province (Big Project + Task List), China (No. STKJ2023009, 20230403).

References

  • 1. Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Piñeros M, Znaor A, Bray F. Cancer statistics for the year 2020: An overview. Int J Cancer. 2021. [Epub ahead of print]. https://doi.org/10.1002/ijc.33588 [PubMed]
  • 2. Cui G, Wu J, Lin J, Liu W, Chen P, Yu M, Zhou D, Yao G. Graphene-based nanomaterials for breast cancer treatment: promising therapeutic strategies. J Nanobiotechnology. 2021; 19:211. https://doi.org/10.1186/s12951-021-00902-8 [PubMed]
  • 3. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020; 70:7–30. https://doi.org/10.3322/caac.21590 [PubMed]
  • 4. Xu X, Zhang M, Xu F, Jiang S. Wnt signaling in breast cancer: biological mechanisms, challenges and opportunities. Mol Cancer. 2020; 19:165. https://doi.org/10.1186/s12943-020-01276-5 [PubMed]
  • 5. Bakir B, Chiarella AM, Pitarresi JR, Rustgi AK. EMT, MET, Plasticity, and Tumor Metastasis. Trends Cell Biol. 2020; 30:764–76. https://doi.org/10.1016/j.tcb.2020.07.003 [PubMed]
  • 6. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, Campbell LL, Polyak K, Brisken C, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008; 133:704–15. https://doi.org/10.1016/j.cell.2008.03.027 [PubMed]
  • 7. Taki M, Abiko K, Ukita M, Murakami R, Yamanoi K, Yamaguchi K, Hamanishi J, Baba T, Matsumura N, Mandai M. Tumor Immune Microenvironment during Epithelial-Mesenchymal Transition. Clin Cancer Res. 2021; 27:4669–79. https://doi.org/10.1158/1078-0432.CCR-20-4459 [PubMed]
  • 8. Shibue T, Weinberg RA. EMT, CSCs, and drug resistance: the mechanistic link and clinical implications. Nat Rev Clin Oncol. 2017; 14:611–29. https://doi.org/10.1038/nrclinonc.2017.44 [PubMed]
  • 9. Saliminejad K, Khorram Khorshid HR, Soleymani Fard S, Ghaffari SH. An overview of microRNAs: Biology, functions, therapeutics, and analysis methods. J Cell Physiol. 2019; 234:5451–65. https://doi.org/10.1002/jcp.27486 [PubMed]
  • 10. Shi Y, Liu Z, Lin Q, Luo Q, Cen Y, Li J, Fang X, Gong C. MiRNAs and Cancer: Key Link in Diagnosis and Therapy. Genes (Basel). 2021; 12:1289. https://doi.org/10.3390/genes12081289 [PubMed]
  • 11. Feng J, Hu S, Liu K, Sun G, Zhang Y. The Role of MicroRNA in the Regulation of Tumor Epithelial-Mesenchymal Transition. Cells. 2022; 11:1981. https://doi.org/10.3390/cells11131981 [PubMed]
  • 12. Pan G, Liu Y, Shang L, Zhou F, Yang S. EMT-associated microRNAs and their roles in cancer stemness and drug resistance. Cancer Commun (Lond). 2021; 41:199–217. https://doi.org/10.1002/cac2.12138 [PubMed]
  • 13. Garofalo M, Quintavalle C, Romano G, Croce CM, Condorelli G. miR221/222 in cancer: their role in tumor progression and response to therapy. Curr Mol Med. 2012; 12:27–33. https://doi.org/10.2174/156652412798376170 [PubMed]
  • 14. Stinson S, Lackner MR, Adai AT, Yu N, Kim HJ, O'Brien C, Spoerke J, Jhunjhunwala S, Boyd Z, Januario T, Newman RJ, Yue P, Bourgon R, et al. miR-221/222 targeting of trichorhinophalangeal 1 (TRPS1) promotes epithelial-to-mesenchymal transition in breast cancer. Sci Signal. 2011; 4:pt5. https://doi.org/10.1126/scisignal.2002258 [PubMed]
  • 15. Liang YK, Lin HY, Dou XW, Chen M, Wei XL, Zhang YQ, Wu Y, Chen CF, Bai JW, Xiao YS, Qi YZ, Kruyt FAE, Zhang GJ. MiR-221/222 promote epithelial-mesenchymal transition by targeting Notch3 in breast cancer cell lines. NPJ Breast Cancer. 2018; 4:20. https://doi.org/10.1038/s41523-018-0073-7 [PubMed]
  • 16. Hashimoto Y, Akiyama Y, Yuasa Y. Multiple-to-multiple relationships between microRNAs and target genes in gastric cancer. PLoS One. 2013; 8:e62589. https://doi.org/10.1371/journal.pone.0062589 [PubMed]
  • 17. Sticht C, De La Torre C, Parveen A, Gretz N. miRWalk: An online resource for prediction of microRNA binding sites. PLoS One. 2018; 13:e0206239. https://doi.org/10.1371/journal.pone.0206239 [PubMed]
  • 18. Zhao M, Liu Y, Zheng C, Qu H. dbEMT 2.0: An updated database for epithelial-mesenchymal transition genes with experimentally verified information and precalculated regulation information for cancer metastasis. J Genet Genomics. 2019; 46:595–7. https://doi.org/10.1016/j.jgg.2019.11.010 [PubMed]
  • 19. Szklarczyk D, Gable AL, Lyon D, Junge A, Wyder S, Huerta-Cepas J, Simonovic M, Doncheva NT, Morris JH, Bork P, Jensen LJ, Mering CV. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 2019; 47:D607–13. https://doi.org/10.1093/nar/gky1131 [PubMed]
  • 20. Zhang Q, Fang Y, She C, Zheng R, Hong C, Chen C, Wu J. Diagnostic and prognostic significance of SLC50A1 expression in patients with primary early breast cancer. Exp Ther Med. 2022; 24:616. https://doi.org/10.3892/etm.2022.11553 [PubMed]
  • 21. Hänzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics. 2013; 14:7. https://doi.org/10.1186/1471-2105-14-7 [PubMed]
  • 22. Thorsson V, Gibbs DL, Brown SD, Wolf D, Bortone DS, Ou Yang TH, Porta-Pardo E, Gao GF, Plaisier CL, Eddy JA, Ziv E, Culhane AC, Paull EO, et al, and Cancer Genome Atlas Research Network. The Immune Landscape of Cancer. Immunity. 2018; 48:812–30.e14. https://doi.org/10.1016/j.immuni.2018.03.023 [PubMed]
  • 23. Bonneville R, Krook MA, Kautto EA, Miya J, Wing MR, Chen HZ, Reeser JW, Yu L, Roychowdhury S. Landscape of Microsatellite Instability Across 39 Cancer Types. JCO Precis Oncol. 2017; 2017:PO.17.00073. https://doi.org/10.1200/PO.17.00073 [PubMed]
  • 24. Malta TM, Sokolov A, Gentles AJ, Burzykowski T, Poisson L, Weinstein JN, Kamińska B, Huelsken J, Omberg L, Gevaert O, Colaprico A, Czerwińska P, Mazurek S, et al, and Cancer Genome Atlas Research Network. Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation. Cell. 2018; 173:338–54.e15. https://doi.org/10.1016/j.cell.2018.03.034 [PubMed]
  • 25. Yang W, Soares J, Greninger P, Edelman EJ, Lightfoot H, Forbes S, Bindal N, Beare D, Smith JA, Thompson IR, Ramaswamy S, Futreal PA, Haber DA, et al. Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Res. 2013; 41:D955–61. https://doi.org/10.1093/nar/gks1111 [PubMed]
  • 26. Kumar A, Golani A, Kumar LD. EMT in breast cancer metastasis: an interplay of microRNAs, signaling pathways and circulating tumor cells. Front Biosci (Landmark Ed). 2020; 25:979–1010. https://doi.org/10.2741/4844 [PubMed]
  • 27. Hwang MS, Yu N, Stinson SY, Yue P, Newman RJ, Allan BB, Dornan D. miR-221/222 targets adiponectin receptor 1 to promote the epithelial-to-mesenchymal transition in breast cancer. PLoS One. 2013; 8:e66502. https://doi.org/10.1371/journal.pone.0066502 [PubMed]
  • 28. Li F. Expression of miR-221 and miR-489 in breast cancer patients and their relationship with prognosis. Oncol Lett. 2020; 19:1523–9. https://doi.org/10.3892/ol.2019.11196 [PubMed]
  • 29. Abak A, Amini S, Estiar MA, Montazeri V, Sakhinia E, Abhari A. Analysis of miRNA-221 Expression Level in Tumors and Marginal Biopsies from Patients with Breast Cancer (Cross-Sectional Observational Study). Clin Lab. 2018; 64:169–75. https://doi.org/10.7754/Clin.Lab.2017.170821 [PubMed]
  • 30. Li Y, Liang C, Ma H, Zhao Q, Lu Y, Xiang Z, Li L, Qin J, Chen Y, Cho WC, Pestell RG, Liang L, Yu Z. miR-221/222 promotes S-phase entry and cellular migration in control of basal-like breast cancer. Molecules. 2014; 19:7122–37. https://doi.org/10.3390/molecules19067122 [PubMed]
  • 31. Di Leva G, Gasparini P, Piovan C, Ngankeu A, Garofalo M, Taccioli C, Iorio MV, Li M, Volinia S, Alder H, Nakamura T, Nuovo G, Liu Y, et al. MicroRNA cluster 221-222 and estrogen receptor alpha interactions in breast cancer. J Natl Cancer Inst. 2010; 102:706–21. https://doi.org/10.1093/jnci/djq102 [PubMed]
  • 32. Xu M, Wang S, Wang Y, Wu H, Frank JA, Zhang Z, Luo J. Role of p38γ MAPK in regulation of EMT and cancer stem cells. Biochim Biophys Acta Mol Basis Dis. 2018; 1864:3605–17. https://doi.org/10.1016/j.bbadis.2018.08.024 [PubMed]
  • 33. Teixeira AL, Gomes M, Medeiros R. EGFR signaling pathway and related-miRNAs in age-related diseases: the example of miR-221 and miR-222. Front Genet. 2012; 3:286. https://doi.org/10.3389/fgene.2012.00286 [PubMed]
  • 34. Masuda H, Zhang D, Bartholomeusz C, Doihara H, Hortobagyi GN, Ueno NT. Role of epidermal growth factor receptor in breast cancer. Breast Cancer Res Treat. 2012; 136:331–45. https://doi.org/10.1007/s10549-012-2289-9 [PubMed]
  • 35. Hsu JL, Hung MC. The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer. Cancer Metastasis Rev. 2016; 35:575–88. https://doi.org/10.1007/s10555-016-9649-6 [PubMed]
  • 36. Xia L, Zheng ZZ, Liu JY, Chen YJ, Ding JC, Xia NS, Luo WX, Liu W. EGFR-targeted CAR-T cells are potent and specific in suppressing triple-negative breast cancer both in vitro and in vivo. Clin Transl Immunology. 2020; 9:e01135. https://doi.org/10.1002/cti2.1135 [PubMed]
  • 37. Kasprzak A. Insulin-Like Growth Factor 1 (IGF-1) Signaling in Glucose Metabolism in Colorectal Cancer. Int J Mol Sci. 2021; 22:6434. https://doi.org/10.3390/ijms22126434 [PubMed]
  • 38. Cevenini A, Orrù S, Mancini A, Alfieri A, Buono P, Imperlini E. Molecular Signatures of the Insulin-like Growth Factor 1-mediated Epithelial-Mesenchymal Transition in Breast, Lung and Gastric Cancers. Int J Mol Sci. 2018; 19:2411. https://doi.org/10.3390/ijms19082411 [PubMed]
  • 39. Elster N, Toomey S, Fan Y, Cremona M, Morgan C, Weiner Gorzel K, Bhreathnach U, Milewska M, Murphy M, Madden S, Naidoo J, Fay J, Kay E, et al. Frequency, impact and a preclinical study of novel ERBB gene family mutations in HER2-positive breast cancer. Ther Adv Med Oncol. 2018; 10:1758835918778297. https://doi.org/10.1177/1758835918778297 [PubMed]
  • 40. Nami B, Wang Z. HER2 in Breast Cancer Stemness: A Negative Feedback Loop towards Trastuzumab Resistance. Cancers (Basel). 2017; 9:40. https://doi.org/10.3390/cancers9050040 [PubMed]
  • 41. Ingthorsson S, Andersen K, Hilmarsdottir B, Maelandsmo GM, Magnusson MK, Gudjonsson T. HER2 induced EMT and tumorigenicity in breast epithelial progenitor cells is inhibited by coexpression of EGFR. Oncogene. 2016; 35:4244–55. https://doi.org/10.1038/onc.2015.489 [PubMed]
  • 42. Försti A, Jin Q, Altieri A, Johansson R, Wagner K, Enquist K, Grzybowska E, Pamula J, Pekala W, Hallmans G, Lenner P, Hemminki K. Polymorphisms in the KDR and POSTN genes: association with breast cancer susceptibility and prognosis. Breast Cancer Res Treat. 2007; 101:83–93. https://doi.org/10.1007/s10549-006-9265-1 [PubMed]
  • 43. Yan JD, Liu Y, Zhang ZY, Liu GY, Xu JH, Liu LY, Hu YM. Expression and prognostic significance of VEGFR-2 in breast cancer. Pathol Res Pract. 2015; 211:539–43. https://doi.org/10.1016/j.prp.2015.04.003 [PubMed]
  • 44. Dai X, Mei Y, Chen X, Cai D. ANLN and KDR Are Jointly Prognostic of Breast Cancer Survival and Can Be Modulated for Triple Negative Breast Cancer Control. Front Genet. 2019; 10:790. https://doi.org/10.3389/fgene.2019.00790 [PubMed]
  • 45. Suh J, Kim DH, Lee YH, Jang JH, Surh YJ. Fibroblast growth factor-2, derived from cancer-associated fibroblasts, stimulates growth and progression of human breast cancer cells via FGFR1 signaling. Mol Carcinog. 2020; 59:1028–40. https://doi.org/10.1002/mc.23233 [PubMed]
  • 46. Santolla MF, Vivacqua A, Lappano R, Rigiracciolo DC, Cirillo F, Galli GR, Talia M, Brunetti G, Miglietta AM, Belfiore A, Maggiolini M. GPER Mediates a Feedforward FGF2/FGFR1 Paracrine Activation Coupling CAFs to Cancer Cells toward Breast Tumor Progression. Cells. 2019; 8:223. https://doi.org/10.3390/cells8030223 [PubMed]
  • 47. He S, Zhang G, Dong H, Ma M, Sun Q. miR-203 facilitates tumor growth and metastasis by targeting fibroblast growth factor 2 in breast cancer. Onco Targets Ther. 2016; 9:6203–10. https://doi.org/10.2147/OTT.S108712 [PubMed]
  • 48. Chen X, Zhao H, Chen C, Li J, He J, Fu X, Zhao H. The HPA/SDC1 axis promotes invasion and metastasis of pancreatic cancer cells by activating EMT via FGF2 upregulation. Oncol Lett. 2020; 19:211–20. https://doi.org/10.3892/ol.2019.11121 [PubMed]
  • 49. Schelch K, Wagner C, Hager S, Pirker C, Siess K, Lang E, Lin R, Kirschner MB, Mohr T, Brcic L, Marian B, Holzmann K, Grasl-Kraupp B, et al. FGF2 and EGF induce epithelial-mesenchymal transition in malignant pleural mesothelioma cells via a MAPKinase/MMP1 signal. Carcinogenesis. 2018; 39:534–45. https://doi.org/10.1093/carcin/bgy018 [PubMed]
  • 50. Schulmeyer CE, Fasching PA, Häberle L, Meyer J, Schneider M, Wachter D, Ruebner M, Pöschke P, Beckmann MW, Hartmann A, Erber R, Gass P. Expression of the Immunohistochemical Markers CK5, CD117, and EGFR in Molecular Subtypes of Breast Cancer Correlated with Prognosis. Diagnostics (Basel). 2023; 13:372. https://doi.org/10.3390/diagnostics13030372 [PubMed]
  • 51. López-Mejía JA, Tallabs-Utrilla LF, Salazar-Sojo P, Mantilla-Ollarves JC, Sánchez-Carballido MA, Rocha-Zavaleta L. c-Kit Induces Migration of Triple-Negative Breast Cancer Cells and Is a Promising Target for Tyrosine Kinase Inhibitor Treatment. Int J Mol Sci. 2022; 23:8702. https://doi.org/10.3390/ijms23158702 [PubMed]
  • 52. Luo Y, Huang W, Zhang H, Liu G. Prognostic significance of CD117 expression and TP53 missense mutations in triple-negative breast cancer. Oncol Lett. 2018; 15:6161–70. https://doi.org/10.3892/ol.2018.8104 [PubMed]
  • 53. Janostiak R, Vyas M, Cicek AF, Wajapeyee N, Harigopal M. Loss of c-KIT expression in breast cancer correlates with malignant transformation of breast epithelium and is mediated by KIT gene promoter DNA hypermethylation. Exp Mol Pathol. 2018; 105:41–9. https://doi.org/10.1016/j.yexmp.2018.05.011 [PubMed]
  • 54. Roussidis AE, Theocharis AD, Tzanakakis GN, Karamanos NK. The importance of c-Kit and PDGF receptors as potential targets for molecular therapy in breast cancer. Curr Med Chem. 2007; 14:735–43. https://doi.org/10.2174/092986707780090963 [PubMed]
  • 55. Brown WS, Tan L, Smith A, Gray NS, Wendt MK. Covalent Targeting of Fibroblast Growth Factor Receptor Inhibits Metastatic Breast Cancer. Mol Cancer Ther. 2016; 15:2096–106. https://doi.org/10.1158/1535-7163.MCT-16-0136 [PubMed]
  • 56. Elbauomy Elsheikh S, Green AR, Lambros MB, Turner NC, Grainge MJ, Powe D, Ellis IO, Reis-Filho JS. FGFR1 amplification in breast carcinomas: a chromogenic in situ hybridisation analysis. Breast Cancer Res. 2007; 9:R23. https://doi.org/10.1186/bcr1665 [PubMed]
  • 57. Mouron S, Manso L, Caleiras E, Rodriguez-Peralto JL, Rueda OM, Caldas C, Colomer R, Quintela-Fandino M, Bueno MJ. FGFR1 amplification or overexpression and hormonal resistance in luminal breast cancer: rationale for a triple blockade of ER, CDK4/6, and FGFR1. Breast Cancer Res. 2021; 23:21. https://doi.org/10.1186/s13058-021-01398-8 [PubMed]
  • 58. Liao S, Liu C, Zhu G, Wang K, Yang Y, Wang C. Relationship between SDC1 and cadherin signalling activation in cancer. Pathol Res Pract. 2020; 216:152756. https://doi.org/10.1016/j.prp.2019.152756 [PubMed]
  • 59. Qiao W, Liu H, Guo W, Li P, Deng M. Prognostic and clinical significance of syndecan-1 expression in breast cancer: A systematic review and meta-analysis. Eur J Surg Oncol. 2019; 45:1132–7. https://doi.org/10.1016/j.ejso.2018.12.019 [PubMed]
  • 60. Kind S, Jaretzke A, Büscheck F, Möller K, Dum D, Höflmayer D, Hinsch A, Weidemann S, Fraune C, Möller-Koop C, Hube-Magg C, Simon R, Wilczak W, et al. A shift from membranous and stromal syndecan-1 (CD138) expression to cytoplasmic CD138 expression is associated with poor prognosis in breast cancer. Mol Carcinog. 2019; 58:2306–15. https://doi.org/10.1002/mc.23119 [PubMed]
  • 61. Cui X, Jing X, Yi Q, Long C, Tian J, Zhu J. Clinicopathological and prognostic significance of SDC1 overexpression in breast cancer. Oncotarget. 2017; 8:111444–55. https://doi.org/10.18632/oncotarget.22820 [PubMed]
  • 62. Yoshimura N, Sano H, Hashiramoto A, Yamada R, Nakajima H, Kondo M, Oka T. The expression and localization of fibroblast growth factor-1 (FGF-1) and FGF receptor-1 (FGFR-1) in human breast cancer. Clin Immunol Immunopathol. 1998; 89:28–34. https://doi.org/10.1006/clin.1998.4551 [PubMed]
  • 63. Mori S, Kodaira M, Ito A, Okazaki M, Kawaguchi N, Hamada Y, Takada Y, Matsuura N. Enhanced Expression of Integrin αvβ3 Induced by TGF-β Is Required for the Enhancing Effect of Fibroblast Growth Factor 1 (FGF1) in TGF-β-Induced Epithelial-Mesenchymal Transition (EMT) in Mammary Epithelial Cells. PLoS One. 2015; 10:e0137486. https://doi.org/10.1371/journal.pone.0137486 [PubMed]
  • 64. Bansal GS, Yiangou C, Coope RC, Gomm JJ, Luqmani YA, Coombes RC, Johnston CL. Expression of fibroblast growth factor 1 is lower in breast cancer than in the normal human breast. Br J Cancer. 1995; 72:1420–6. https://doi.org/10.1038/bjc.1995.524 [PubMed]
  • 65. Gao Y, Wang Y, Yu J, Guo R. FGF Exhibits an Important Biological Role on Regulating Cell Proliferation of Breast Cancer When it Transports Into The Cell Nuclei. Cell Biochem Biophys. 2022; 80:311–20. https://doi.org/10.1007/s12013-021-01044-2 [PubMed]
  • 66. Shi H, Fu C, Wang W, Li Y, Du S, Cao R, Chen J, Sun D, Zhang Z, Wang X, Zhu X. The FGF-1-specific single-chain antibody scFv1C9 effectively inhibits breast cancer tumour growth and metastasis. J Cell Mol Med. 2014; 18:2061–70. https://doi.org/10.1111/jcmm.12371 [PubMed]
  • 67. Di D, Chen L, Guo Y, Wang L, Wang H, Ju J. Association of BCSC-1 and MMP-14 with human breast cancer. Oncol Lett. 2018; 15:5020–6. https://doi.org/10.3892/ol.2018.7972 [PubMed]
  • 68. Cui G, Cai F, Ding Z, Gao L. MMP14 predicts a poor prognosis in patients with colorectal cancer. Hum Pathol. 2019; 83:36–42. https://doi.org/10.1016/j.humpath.2018.03.030 [PubMed]
  • 69. Wang X, Meng Q, Wang Y, Gao Y. Overexpression of MMP14 predicts the poor prognosis in gastric cancer: Meta-analysis and database validation. Medicine (Baltimore). 2021; 100:e26545. https://doi.org/10.1097/MD.0000000000026545 [PubMed]
  • 70. Wang JF, Gong YQ, He YH, Ying WW, Li XS, Zhou XF, Zhou LQ. High expression of MMP14 is associated with progression and poor short-term prognosis in muscle-invasive bladder cancer. Eur Rev Med Pharmacol Sci. 2020; 24:6605–15. https://doi.org/10.26355/eurrev_202006_21646 [PubMed]
  • 71. Yan T, Lin Z, Jiang J, Lu S, Chen M, Que H, He X, Que G, Mao J, Xiao J, Zheng Q. MMP14 regulates cell migration and invasion through epithelial-mesenchymal transition in nasopharyngeal carcinoma. Am J Transl Res. 2015; 7:950–8. [PubMed]
  • 72. Zuo QF, Cao LY, Yu T, Gong L, Wang LN, Zhao YL, Xiao B, Zou QM. MicroRNA-22 inhibits tumor growth and metastasis in gastric cancer by directly targeting MMP14 and Snail. Cell Death Dis. 2015; 6:e2000. https://doi.org/10.1038/cddis.2015.297 [PubMed]
Download PDF
Corresponding Authors

Jundong Wu
wujun-dong@163.com
https://orcid.org/0000-0003-0607-8960

Cuiping Guo
cuipingguo@yeah.net
https://orcid.org/0009-0003-0176-3843

Keywords
breast cancer miR-221-3p epithelial-mesenchymal transition target gene diagnosis prognosis immune infiltration drug sensitivity
Paper Sections